SpiderRock Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$1.49M Sell
12,506
-2,724
-18% -$363K 0.02% 381
2024
Q2
$2.17M Buy
15,230
+223
+1% +$29.6K 0.04% 260
2024
Q1
$1.99M Buy
+15,007
New +$1.79M 0.05% 263

Other funds holding NVO

SpiderRock Advisors's NVO Position: Q3 2024 in Review

SpiderRock Advisors reduced its Novo Nordisk (NVO) stake by 18% in Q3 2024, selling an estimated $363K and leaving 12,506 shares worth $1.49M. The position accounts for 0.02% of the portfolio, ranked #381.

SpiderRock Advisors first reported a position in NVO in Q1 2024 and has held it in 3 quarters since. The position peaked at $2.17M in Q2 2024. 1,786 funds tracked by Wall St. Rank hold NVO as of Q3 2024.

  • SpiderRock Advisors held 12,506 shares of Novo Nordisk worth $1.49M as of Q3 2024.
  • SpiderRock Advisors sold 2,724 Novo Nordisk shares in Q3 2024, an estimated $363K.
  • Novo Nordisk made up 0.02% of SpiderRock Advisors's portfolio in Q3 2024, its #381 holding.
  • SpiderRock Advisors first reported a position in Novo Nordisk in Q1 2024 and has held it in 3 quarters since.
  • SpiderRock Advisors's Novo Nordisk position peaked at $2.17M in Q2 2024.
  • 1,786 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.